| 冯 凯,吴梓政,韦丽光,谭智慧,韩 猛,孙敬岩.改良乳腺癌根治术联合表柔比星治疗乳腺癌的疗效及对血清抵抗素、脂联素水平的影响[J].现代生物医学进展英文版,2021,(5):977-981. |
| 改良乳腺癌根治术联合表柔比星治疗乳腺癌的疗效及对血清抵抗素、脂联素水平的影响 |
| Effect of Modified Radical Mastectomy Combined with Epirubicin in the Treatment of Breast Cancer and Research Progress on Serum Resistin and Adiponectin Levels |
| Received:September 07, 2021 Revised:September 30, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.05.038 |
| 中文关键词: 改良乳腺癌根治术 表柔比星 血清抵抗素 脂联素 |
| 英文关键词: Modified radical mastectomy Epirubicin Serum resistin Adiponectin |
| 基金项目:河北省医学科学研究重点计划项目（20150343） |
|
| Hits: 773 |
| Download times: 600 |
| 中文摘要: |
| 摘要 目的：探究改良乳腺癌根治术联合表柔比星治疗乳腺癌的疗效及对血清抵抗素、脂联素水平的影响。方法：收集2019年1月～2020年1月我院确诊为乳腺癌的60例患者资料，使用随机数字法将患者分为对照组、观察组，每组30例。两组患者均接受改良乳腺癌根治术，对照组患者在此基础上接受阿霉素、环磷酰胺、5-氟尿嘧啶治疗，观察组接受表；柔比星与环磷酰胺联合化疗方案治疗，比较两组患者治疗效果、不良反应发生率、3年生存率、血清抵抗素、脂联素水平。结果：观察组临床疗效（93.33 %）高于对照组患者（60.00 %）：（P<0.05）；观察组心脏毒性、中性粒细胞减少发生率（13.33 %，73.33 %）低于对照组患（30.00%，86.67 %）（P<0.05）。两组患者恶心呕吐、肝功能损害发生率相比，差异无统计学意义（P>0.05）。观察组术后3年生存率（76.67 %）高于对照组患者（63.33 %）（P<0.05）。两组患者治疗后血清抵抗素及脂联素水平均有好转（P<0.05），观察组血清抵抗素水平低于对照组（P<0.05），观察组脂联素水平高于对照组（P<0.05）。结论：改良乳腺癌根治术联合表柔比星治疗乳腺癌疗效较好，可有效改善血清抵抗素水平、脂联素水平。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the effect of modified radical mastectomy combined with epirubicin in the treatment of breast cancer and its influence on serum resistin and adiponectin levels. Methods: The data of 60 patients with breast cancer diagnosed in our hospital from January 2019 to January 2020 were collected and randomly divided into control group and observation group, 30 cases in each group. Two groups of patientsreceived modified radical mastectomy, the control group received adriamycin, cyclophosphamide, 5-fluorouracil on the basis of the treatment, the observation group received epirubicin and cyclophosphamide combined chemotherapy. The treatment effect, adverse reaction rate, 3-year survival rate, serum resistin and adiponectin levels were compared between the two groups. Results: The clinical efficacy of the observation group (93.33 %) was higher than that of the control group (60.00 %) (P<0.05); the incidence of cardiotoxicity and neutropenia in the observation group (13.33 %, 73.33 %) was lower than that in the control group (30.00 %, 86.67 %) (P<0.05). There was no significant difference in the incidence of nausea, vomiting and liver function damage between the two groups (P>0.05). The 3-year survival rate of the observation group (76.67 %) was higher than that of the control group (63.33 %) (P<0.05). After treatment, the serum resistin and adiponectin levels of the two groups were improved (P<0.05), the serum resistin level in the observation group was lower than that in the control group (P<0.05), and the adiponectin level in the observation group was higher than that in the control group (P<0.05). Conclusion: Modified radical mastectomy combined with epirubicin is effective in the treatment of breast cancer, which can effectively improve the levels of serum resistin and adiponectin. |
|
View Full Text
View/Add Comment Download reader |
| Close |
